Influence of α‐Adrenoceptor Agonists and Antagonists on Imipramine‐Induced Hypothermia in Mice

Abstract: Effects of adrenoceptor agonists and antagonists on imipramine‐induced hypothermia in mice were studied. Intraperitoneal injection of imipramine (10–40 mg kg^?1), α₂‐adrenoceptor agonist clonidine (0.05–0.1 mg kg^?1), α₁‐adrenoceptor agonist phenylephrine (6 mg kg^?1) and α₁‐adrenoceptor antagonist prazosin (1–4 mg kg^?1) but not α₂‐adrenoceptor antagonist yohimbine (1–4 mg kg^?1) induced significant hypothermia. The hypothermic response induced by imipramine (10–30 mg kg^?1) was not altered by clonidine (0.05–0.1 mg kg^?1) or phenylephrine (2–6 mg kg^?1). The response of imipramine (10–30 mg kg^?1) was reduced significantly by yohimbine (2 mg kg^?1) and was potentiated by prazosin (1 mg kg^?1). The hypothermic effect of clonidine (0.1 mg kg^?1) and imipramine (20 mg kg^?1) were also decreased significantly by different doses of yohimbine (1–4 mg kg^?1). The hypothermia induced by different doses of prazosin (1–4 mg kg^?1) was not altered by yohimbine (2 mg kg^?1) or by low dose of imipramine (10 mg kg^?1). It is concluded that α₂‐adrenoceptor mechanism may be involved in the hypothermic effect of imipramine.     

Pharmacological Profile of the Vascular Responses to Dopamine in the Canine External Carotid Circulation*

Abstract: The present study investigated the effects of dopamine on the canine external carotid circulation. One min. intracarotid artery (i.c.) infusions of dopamine (10–310 μg min.^?1) produced dose‐dependent decreases in the canine external carotid conductance without affecting blood pressure or heart rate. This effect was mimicked by the D_1/2‐like receptor agonist apomorphine (1–310 μg min^?1), but not by the D₂‐like receptor agonist, bromocriptine (31–310 μg min.^?1). In contrast, fenoldopam (1–310 μg min.^?1, intracarotid), a D₁‐like receptor agonist, produced dose‐dependent increases in external carotid conductance. The vasoconstrictor response to dopamine was abolished after intravenous administration of the antagonists, phentolamine (α_1/2; 2000 μg kg^?1) or rauwolscine (α₂; 100 μg kg^?1), but remained unaffected after prazosin (α₁; 100 μg kg^?1) or haloperidol (D₂‐like; 1000 μg kg^?1). Interestingly, after phentolamine not only were the vasoconstrictor responses to dopamine abolished, but even a dose‐dependent vasodilator component was unmasked. These vasodilator responses to dopamine remained unchanged after intravenous haloperidol or propranolol (1000 μg kg^?1 each). On the other hand, the vasodilator responses to fenoldopam, which remained unchanged after intravenous saline (0.1 ml kg^?1), propranolol (1000 μg kg^?1) or vagosympathectomy, were abolished by the D₁‐like receptor antagonist, SCH‐23390 (10 μg kg^?1). Lastly, the responses to dopamine and fenoldopam were not significantly altered after intraperitoneal pretreatment with reserpine (5 mg kg^?1; ?24 hr). The above results suggest that the canine external carotid vasoconstrictor responses to dopamine: (i) are mainly mediated by α₂‐adrenoceptors; and (ii) overshadow a vasodilator component, which involves vascular D₁‐like receptors.     

Labedipinedilol‐A: A vanilloid‐based α/β‐adrenoceptor blocker with calcium entry blocking and long‐acting antihypertensive properties

The combination of β‐adrenoceptor blockade and vasodilator action have proved highly useful in antihypertensive therapy. Studies of the mechanisms of action of labedipinedilol‐A that combine these effects within a single molecule are described in this report. Intravenous labedipinedilol‐A (0.1–1.0 mg/kg) produced dose‐dependent hypotensive and bradycardia responses for above 1.0 h, significantly different from nifedipine (0.5 mg/kg, i.v.)‐induced hypotensive and reflex tachycardia activities in pentobarbital‐anesthetized Wistar rats. Pretreatment with labedipinedilol‐A also inhibited phenylephrine (20 μg/kg, i.v.)‐induced hypertensive and (‐)isoprenaline (0.5 μg/kg, i.v.)‐induced tachycardia effects. Oral administration of labedipinedilol‐A (5–50 mg/kg) in spontaneously hypertensive rats (SHR) reduced the blood pressure and heart rate for 24 h but did not increase heart rate. Labedipinedilol‐A (10^–7–10^–5 M) competitively antagonized (‐)isoprenaline (10^–10–10^–4M)‐induced positive chronotropic and inotropic effects of the isolated rat atria and tracheal relaxation responses of the isolated guinea pig tissues. Labedipinedilol‐A also prevented the rate‐increasing effects of increased extracellular Ca²⁺ (3.0–9.0 mM) in a concentration‐dependent manner. In the isolated rat aorta, labedipinedilol‐A competitively antagonized CaCl₂ and norepinephrine‐induced contractions with pKCa^–1 and pA₂ values of 8.46 ± 0.05 and 8.28 ± 0.03 and had a potent effect of inhibiting high K⁺‐induced vasocontraction. Furthermore, labedipinedilol‐A, in an equal antagonist activity, inhibited norepinephrine‐induced phasic and tonic contraction. In the cultured blood vessel smooth muscle cell (A7r5 cell line), KCl, norepinephrine, and Bay K 8644‐induced intracellular calcium changes were decreased after application of labedipinedilol‐A (10^–9–10^–6 M). The binding characteristics of labedipinedilol‐A were evaluated in [³H]CGP‐12177 binding to ventricle and lung and [³H]nitrendipine and [³H]prazosin binding to brain membranes in rats. The ‐logIC₅₀ values of labedipinedilol‐A for β₁‐, β₂‐, and α₁‐adrenoceptor and calcium channel, were 8.17 × 10^–7 M, 8.20 × 10^–7 M, 2.20 × 10^–8 M, and 2.46 × 10^–8 M, respectively. Labedipinedilol‐A‐induced sustained depressor effect was mainly attributed to its calcium entry and α‐adrenoceptor blocking activities in the blood vessel. Sustained bradycardia effect resulted from β‐adrenoceptor and calcium entry blocking, which deleted the sympathetic activation‐associated reflex tachycardia in the heart. Drug Dev. Res. 49:94–108, 2000. © 2000 Wiley‐Liss, Inc.     

Third‐generation dihydropyridine‐type calcium channel blocker labedipinedilol‐B displays α/β‐adrenoceptor blocking activities

The pharmacological properties of labedipinedilol‐B {N‐[4‐[2‐hydroxy‐3‐(2‐methoxy‐1‐oxyethylaminobenzene) propoxy]‐benzyl]‐2,6‐dimethyl‐3,5‐dicarbomethoxy‐1,4‐dihydropyridine} were investigated in vivo and in vitro in comparison with labedipinedilol‐A. Intravenous labedipinedilol‐B (0.5, 1.0, and 3.0 mg kg^–1), produced dose‐dependent hypotensive and bradycardia responses in pentobarbital‐anesthetized Wistar rats. Pretreatment with labedipinedilol‐B (1.0 mg kg^–1, iv) also inhibited phenylephrine (10 μg kg^–1)‐induced hypertensive and (–)isoproterenol (0.5 μg kg^–1)‐induced tachycardia effects. In the isolated Wistar rat right and left atria and guinea pigs tracheal strips experiments, labedipinedilol‐B (10^–7, 10^–6, and 10^–5 M) competitively antagonized the (–)isoproterenol‐induced positive chronotropic and inotropic effects and tracheal relaxation responses in a concentration‐dependent manner. The parallel shift to the right of the concentration–response curve of (–)isoproterenol suggested that labedipinedilol‐B was a β₁/β₂‐adrenoceptor competitive antagonist. Labedipinedilol‐B (10^–7, 10^–6, and 10^–5 M) also prevented the rate‐increasing effects of increased extracellular Ca²⁺ (3.0–9.0 mM) in a concentration‐dependent manner. In the isolated rat aorta, labedipinedilol‐B (10^–7, 10^–6, and 10^–5 M) competitively antagonized the CaCl₂ and norepinephrine‐induced contractions with pKCa^–1 and pA₂ values of 8.02 ± 0.04 and 7.55 ± 0.05 in a concentration‐dependent manner. The parallel shift to the right of the concentration–response curves of norepinephrine suggested that labedipinedilol‐B was an α‐adrenoceptor competitive antagonist. Furthermore, labedipinedilol‐B, in an equal antagonist activity, inhibited norepinephrine‐induced phasic and tonic contraction. In the isolated rat aorta, labedipinedilol‐B also competitively antagonized CaCl₂‐induced contractions and made the parallel shift to the right of the concentration–response curve of CaCl₂. In cultured blood vessel smooth muscle cells (A7r5 cell lines), Bay K 8644‐induced intracellular calcium changes were decreased after application of labedipinedilol‐B, suggesting that the compound was a calcium channel blocker. The binding characteristics of labedipinedilol‐B were evaluated in [³H]CGP‐12177 binding to ventricle and lung and [³H]prazosin binding to brain membranes in rats. Labedipinedilol‐B also was evaluated in [³H]nitrendipine binding to brain membranes in rats. These results indicated that labedipinedilol‐B, similar to labedipinedilol‐A, has α‐adrenoceptor blocking, β‐adrenoceptor blocking, and calcium entry blocking activities in a single compound. We suggest that these two compounds represent a new generation of 1,4‐dihydropyridine‐type calcium channel blockers. Drug Dev. Res. 52:462–474, 2001. © 2001 Wiley‐Liss, Inc.     

Ventricular PKC‐ϵ and humoral signaling in DOCA‐Salt rats treated with labedipinedilol‐A

Effects of oral antihypertensive monotherapy with labedipinedilol‐A, labetalol, atenolol, amlodipine, prazosin (20 mg kg^?1 day^?1), and short‐acting nifedipine (3 mg kg^?1 day^?1) on DOCA‐salt‐induced translocation of ventricular protein kinase C‐?(PKC‐?), humoral signaling, and the cardiovascular system were investigated in rats for 4 weeks. The triple blocking activities of labedipinedilol‐A (α/β‐adrenoceptor blockade and calcium entry blockade) were compared with single blocking activities of selective drugs. Cytosolic PKC‐? immunoreactivity was decreased by labedipinedilol‐A, short‐acting nifedipine, amlodipine, prazosin, labetalol, atenolol, and losartan. Membranous PKC‐? immunoreactivity was significantly decreased by labedipinedilol‐A, amlodipine, prazosin, labetalol, and atenolol. Labedipinedilol‐A and prazosin more potently decreased membranous than cytosolic PKC‐? expression. Labedipinedilol‐A, labetalol, and atenolol effectively inhibited DOCA‐salt‐induced increases in angiotensin II (Ang II). All antihypertensive agents reduced endothelin‐1 (ET‐1) levels in urine and cardiac weight growth. Treatments with labedipinedilol‐A, labetalol, atenolol, and amlodipine normalized DOCA‐salt‐induced ANP increases. Prazosin did not decrease ANP. Short‐acting nifedipine elevated ANP. During long‐term antihypertensive therapy in DOCA‐salt hypertensive rats, single blockade drugs did not fully inhibit ventricular PKC‐? translocation or Ang II, ET‐1, and ANP humoral signaling. However, triple blockade labedipinedilol‐A therapy had a wide range of α/β‐adrenergic receptor and calcium channel inhibitory activities, including diminished reflux tachycardia, inhibition of PKC‐? translocation, and reduction of Ang II, ET‐1, and ANP formation. Drug Dev. Res. 59:307–315, 2003. 2003 Wiley‐Liss, Inc.     

Involvement of presynaptic dopamine receptors in the antihypertensive response to 2-NN-dimetnylamino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene(M-7)

M-7, 1 and 3 mg kg^?1 s.c., elicits an antihypertensive response and bradycardia in conscious spontaneously hypertensive rats (SHR) and causes inhibition of stimulation-evoked pressor responses and tachycardia in pithed SHR. Metoclopramide (30 mg kg^?1 i.p.), but not piperoxan (5 mg kg^?1 i.p.), abolishes the antihypertensive effect and inhibition of stimulation-evoked pressor responses produced by M-7 (1 mg kg^?1 s.c.) in SHR. Conversely, piperoxan, but not metoclopramide, reduces the bradycardia and inhibition of stimulation-evoked tachycardia produced by M-7. Metoclopramide (30 mg kg^?1 i.p.) did not affect the cardiovascular responses elicited by intracerebroventricular administration of either clonidine (1 μg) or M-7 (3 μg). These results suggest that the antihypertensive effect of M-7 may be mediated by stimulation of presynaptic dopamine receptors on sympathetic nerves to the vasculature and is independent of the bradycardia, which is probably due to stimulation of presynaptic α₂-adrenoceptors on cardiac sympathetic nerve endings.     

KMUP 880708: A vanyllilamide‐based β1‐adrenoceptor antagonist with α‐adrenoceptor blocking and potassium channel opening activities

A vanillylamide‐based propanolamine derivative, KMUP 880708, was first investigated both in vivo and in vitro. KMUP 880708 (0.1, 0.5, 1.0, and 2.0 mg kg^–1, iv) produced dose‐dependent hypotensive and bradycardia responses in pentobarbital‐anesthetized Wistar rats. KMUP 880708 (0.1, 0.5, and 1.0 mg kg^–1, iv) also markedly inhibited both the tachycardia effects induced by (–)isoproterenol and arterial pressor responses induced by phenylephrine. KMUP 880708 competitively antagonized (–)isoproterenol‐induced positive inotropic and chronotropic effects of the atria and tracheal relaxation responses on isolated guinea pig tissues. The apparent pA₂ values for KMUP 880708 was 7.82 ± 0.06 in the right atria, 7.51 ± 0.13 in the left atria, and 6.31 ± 0.07 in the trachea, respectively, indicating that KMUP 880708 was selective β₁‐adrenoceptor blocker. In thoracic aorta experiments, KMUP 880708 also produced a competitive antagonism of norepinephrine‐induced contraction with pA₂ value of 7.92 ± 0.52, indicating that KMUP 880708 was α‐adrenoceptor antagonist. In isolated rat thoracic aorta, KMUP 880708 more potently relaxed the contractions induced by phenylephrine (10^–5 M) than those by high K⁺ (75 mM). KMUP 880708‐induced relaxation was significantly reduced by endothelium removal and by exposure to L‐N^G‐nitro arginine methyl ester (L‐NAME, 1 and 3 × 10^–4 M), indomethacin (3 × 10^–5 M), methylene blue (10^–5 M) and 1H‐[1,2,4]oxadiazolol[4,3,‐a]quinoxalin‐1‐one (ODQ, 10^–6 M). The vasorelaxant effect of KMUP 880708 on phenylephrine‐induced contraction was attenuated by the pretreatment with tetraethylammonium (TEA), glibenclamide, charybdotoxin, and apamin, but not by 4‐aminopyridine (4‐AP). In addition, KMUP 880708 inhibited phenylephrine‐induced biphasic contraction and affected the fast‐twitch phase more significantly than the slow tonic phase. In the radioligand‐binding assay, the K_i values of [³H]CGP‐12177 binding to rat ventricle and lung membranes were 15.14 and 524.81 nM, respectively, and the value of [³H]prazosin binding to rat brain membrane was 3.89 nM. The ranking order of inhibition for [³H]CGP‐12177 binding on β‐adrenoceptor was propranolol > labetalol > KMUP 880708 > atenolol, and that for [³H]prazosin binding to α‐adrenoceptor was KMUP 880708 > labetalol. In conclusion, KMUP 880708 was found to be a new generation α/β‐adrenoceptor blocker with selective β₁‐adrenoceptor blocking and vascular smooth muscle relaxation activities. Furthermore, the vasodilator effect of KMUP 880708 is attributed to the release of NO or NO‐related substance from vascular endothelium. While the endothelium‐independent mechanism involved in the relaxation of KMUP 880708 is probably linked to K⁺ channel activation in these vessels. Drug Dev. Res. 55:104–117, 2002. © 2002 Wiley‐Liss, Inc.     

Chronic Clorgyline Induces Selective Down‐Regulation of α2‐Adrenoceptor Agonist Binding Sites in Rat Brain

Inactivation of α₂‐adrenoceptors by N‐ethoxycarbonyl‐2‐ethoxy‐1,2‐dihydroquinoline (EEDQ) has been shown to induce an increase in brain regulatory Gα_i1/2 proteins, which was related to biphasic recovery of agonist binding sites. To investigate further the nature of this phenomenon, the chronic effects of clorgyline (a monoamine oxidase inhibitor antidepressant) on the recovery of α₂‐adrenoceptors after EEDQ and on EEDQ‐induced up‐regulation of Gα_i1/2 proteins were assessed in rat brain. Clorgyline (1 mg kg^?1 for 7–35 days) induced a time‐dependent down‐regulation (20% to 55%) of the density of cortical α₂‐adrenoceptor agonist sites ([³H]UK 14304/bromoxidine binding) but not of antagonist sites ([³H]RX 821002/2‐methoxy idazoxan binding). However, chronic clorgyline did not alter the immunoreactive levels of Gα_i1/2, Gα_i3, and Gα_o proteins in cortex. In clorgyline‐treated rats, the turnover functions for agonist and antagonist binding sites (receptor recovery after EEDQ) were different and indicated that the reduced density of α₂‐adrenoceptor agonist sites induced by clorgyline was due to a greater rate of receptor disappearance. The recovery of [³H]UK 14304 binding in clorgyline‐treated rats did not fit a biphasic recovery model and the turnover parameters were very similar to those obtained for the second phase of recovery (biphasic model) of agonist binding sites in naive rats. This suggested that clorgyline down‐regulated only the α₂‐adrenoceptors of rapid turnover which is associated with the increases in the expression of Gα_i1/2 proteins induced by EEDQ. In this context, clorgyline (1 mg kg^?1 for 7 days) fully prevented the up‐regulation (50%) of brain Gα_i1/2 proteins induced by EEDQ. The results indicate that one relevant mechanism involved in the in vivo desensitization of brain α₂‐adrenoceptors is an effective impairment of receptor‐G protein coupling.     

The α‐adrenoceptor antagonist,zolertine, inhibits α1D‐ and α1A‐adrenoceptor‐mediated vasoconstriction in vitro

1 The antagonist effect of zolertine (4‐phenyl‐1‐[2‐(5‐tetrazolyl)ethyl]piperazine trihydrochloride), on vascular contraction elicited by noradrenaline in aorta, carotid (α1D‐adrenoceptors), mesenteric (α1A/D‐adrenoceptors) and caudal arteries (α1A‐adrenoceptors) from Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats and rabbit aorta (α1B‐adrenoceptors), was investigated in endothelium‐denuded arterial rings.
2 The selective α1D‐adrenoceptor agonist, noradrenaline, elicited concentration‐dependent contractions in all arterial rings from both species. Noradrenaline selectivity was: carotid=aorta>>.Gt;mesenteric=rabbit aorta>caudal arteries.
3 The contractile responses induced by noradrenaline were competitively antagonized by zolertine in rat carotid and aorta arteries, yielding pA2 values of WKY, 7.48±0.18; SHR, 7.43±0.13 and WKY, 7.57±0.24; SHR, 7.40±0.08, respectively. Zolertine was a non‐competitive antagonist in some blood vessels as Schild plot slopes were lower than unity. The pKb estimates for zolertine were WKY, 6.98±0.16; SHR, 6.81±0.18 in the mesenteric artery, WKY, 5.73±0.11; SHR, 5.87±0.25 in the caudal artery and 6.65±0.09 in rabbit aorta.
4 Competition binding experiments using the α1‐adrenoceptor antagonist [³H]prazosin showed a zolertine pKi of 6.81±0.02 in rat liver (α1B‐adrenoceptors) and 6.35±0.04 in rabbit liver (α1A‐adrenoceptors) membranes.
5 Zolertine showed higher affinity for α1D‐adrenoceptors compared to α1A‐adrenoceptors, while it had an intermediate affinity for α1B‐adrenoceptors. The ability of the α1‐adrenoceptor antagonist zolertine to block α1D‐adrenoceptor‐mediated constriction in different vessels of WKY and SHR rats may explain its antihypertensive efficacy despite its low order of potency.     

Antinociceptive Synergism of MD‐354 and Clonidine. Part II. The α2‐Adrenoceptor Component

Abstract: Previously, we reported that antinociceptive synergism of a 5‐HT₃/α₂‐adrenoceptor ligand MD‐354 (m‐chlorophenylguanidine) and clonidine combination occurs, in part, through a 5‐HT₃ receptor antagonist mechanism. In the present investigation, a possible role for α₂‐adrenoceptors was examined. Mechanistic studies using yohimbine (a subtype non‐selective α₂‐adrenoceptor antagonist), BRL 44408 (a preferential α_2A‐adrenoceptor antagonist) and imiloxan (a preferential α_2B/C‐adrenoceptor antagonist) on the antinociceptive actions of a MD‐354/clonidine combination were conducted. Subcutaneous pre‐treatment with all three antagonists inhibited the antinociceptive synergism of MD‐354 and clonidine in the mouse tail‐flick assay in a dose‐dependent manner (AD₅₀ = 0.33, 2.1, and 0.17 mg/kg, respectively). Enhancement of clonidine antinociception by MD‐354 did not potentiate clonidine’s locomotor suppressant activity in a mouse locomotor assay. When [ethyl‐³H]RS‐79948‐197 was used as radioligand, MD‐354 displayed almost equal affinity to α_2A‐ and α_2B‐adrenoceptors (K_i = 110 and 220 nM) and showed lower affinity at α_2C‐adrenoceptors (K_i = 4,700 nM). MD‐354 had no subtype‐selectivity for the α₂‐adrenoceptor subtypes as an antagonist in functional [³⁵S]GTPγS binding assays. MD‐354 was a weak partial agonist at α_2A‐adrenoceptors. Overall, in addition to the 5‐HT₃ receptor component, the present investigation found MD‐354 to be a weak partial α_2A‐adrenoceptor agonist that enhances clonidine’s thermal antinociceptive actions through an α₂‐adrenoceptor‐mediated mechanism without augmenting sedation.     

Comparative Cardiovascular Effects of the Angiotensin II Type 1 Receptor Antagonists ZD 7155 and Losartan in the Rat

Binding experiments show that ZD 7155 is a potent angiotensin II type 1 receptor antagonist. In this study this novel substance was studied in normotensive and hypertensive rats. The relative potency and duration of the antihypertensive effects of ZD 7155 were compared with those of the reference substance, losartan. The inhibitory effects of both compounds on angiotensin II-induced pressor actions were studied in the conscious normotensive Sprague-Dawley (SD) rat and in the conscious, spontaneously hypertensive rat (SHR). Arterial blood pressure and heart rate (HR) were obtained by direct intraarterial recording. Angiotensin II infusion was administered intravenously in the dose range 53.3 ng—12.8 μg kg^?1 min^?1 to the conscious rats. ZD 7155 was administered in a bolus dose of 1.082 μmol kg^?1 (0.51 mg kg^?1) and losartan in bolus doses of 2.165 and 6.495 μmol kg^?1 (1.0 and 3.0 mg kg^?1). In conscious SD rats, ZD 7155 and losartan behaved as competitive antagonists and the pressor response curve to angiotensin II was shifted to the right. Experiments in conscious SD rats also showed that ZD 7155 was approximately ten times as potent as losartan in suppressing the angiotensin II-induced pressor response (240 ng kg^?1; 10 min infusion). In addition, experiments with conscious rats demonstrated that ZD 7155 could suppress the angiotensin II-induced pressor response for approximately 24 h when ZD 7155 was administered intravenously in a 1.082 μmol kg^?1 bolus dose and angiotensin II was given at 240 ng kg^?1 (in a 10?min infusion). Experiments in conscious SHRs using ZD 7155 (1.082 μmol kg^?1) and losartan (6.495 μmol kg^?1) as intravenous boluses indicated that both ZD 7155 and the reference compound losartan exhibited a significant antihypertensive effect. These results demonstrate that ZD 7155 is a potent angiotensin II-type 1 antagonist which is approximately ten times as potent as losartan in suppressing the angiotensin II-induced pressor response. Furthermore, ZD 7155 may suppress the angiotensin II-induced pressor response for 24 h and in the SHR ZD 7155 induces a pronounced and persistent antihypertensive effect.     

Ferulidilol: A vasodilatory and antioxidant adrenoceptor and calcium entry blocker,with ancillary β2‐agonist activity

Intravenous injection of ferulidilol (0.5, 1.0, 1.5 mg kg⁻¹) produced dose‐dependent hypotensive and bradycardia responses in pentobarbital‐anesthetized Wistar rats. Ferulidilol competitively antagonized (‐)isoprenaline‐induced positive inotropic and chronotropic effects of the atria and tracheal relaxation responses on isolated guinea pig tissues. The parallel shift to the right of the concentration–response curve of (‐)isoprenaline suggested that ferulidilol was a β‐adrenoceptor antagonist. The apparent pA₂ values were 8.04 ± 0.09 for the right atria, 8.03 ± 0.15 for the left atria, and 7.51 ± 0.06 for the trachea, respectively. Ferulidilol was more potent than labetalol. In thoracic aorta experiments, ferulidilol also produced a competitive antagonism of norepinephrine‐ and CaCl₂‐induced contraction with pA₂ and pKCa⁻¹ values of 7.05 ± 0.03 and 6.04 ± 0.05, respectively. Ferulidilol produced cumulative relaxation responses on isolated tracheal strips from reserpine‐treated guinea pigs. The effects were competitively antagonized by ICI 118,551 (10⁻⁸–10⁻⁶ M), a relatively selective β₂‐adrenoceptor antagonist. The results implied that ferulidilol had partial β₂‐agonist activity. In the radioligand binding assay, ferulidilol produced dose‐dependent inhibition of [³H]CGP‐12177 binding to rat ventricle and lung membranes with K_i values of 3.40 and 17.94 nM, respectively. In addition, ferulidilol also antagonized [³H]prazosin and [³H]nitrendipine binding to rat brain membrane with K_i values of 32.48 and 305.01 nM, respectively. These results further confirmed the α/β and calcium entry blocking activities of ferulidilol described in functional studies. Furthermore, ferulidilol (10⁻⁸–10⁻⁵ M] inhibited lipid peroxidation induced by Fe²⁺ and ascorbic acid, indicating that it possesses the antioxidant activity inherent in ferulic acid. Our results demonstrate that ferulidilol is a new generation α/β‐adrenoceptor blocker with ancillary calcium entry blockade, partial β₂‐agonist activities and additional antioxidant effects. Drug Dev. Res. 47:77–89, 1999. © 1999 Wiley‐Liss, Inc.     

AG‐4: a nicotinic agonist endowed with antiamnesic properties

The effect of the nicotinic agonist AG‐4 on memory processes was evaluated in the mouse passive avoidance test. AG‐4 (100 μg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg^–1 ip), mecamylamine (20 mg kg^–1 ip), and dihydro‐β‐erythroidine (10 μg per mouse icv). In the same experimental conditions, AG‐4 (100 μg per mouse icv) also prevented baclofen (2 mg kg^–1 ip), clonidine (0.125 mg kg^–1 ip), and diphenhydramine (20 mg kg^–1 ip) amnesia in mice. AG‐4 exerted an antiamnesic effect comparable to that produced by nicotine (2 mg kg^–1 ip), physostigmine (0.2 mg kg^–1 ip), and the nootropic drug piracetam (30 mg kg^–1 ip). At the active dose, AG‐4 did not impair mice motor coordination and spontaneous motility as revealed, respectively, by Rota‐rod test and Animex apparatus. Present results evidence the antiamnesic activity of the nicotinic agonist AG‐4 suggesting a potential employment of this compound in the symptomatic treatment of cognitive impairments. Drug Dev. Res. 51:191–196, 2000. © 2001 Wiley‐Liss, Inc.     

Impairment of α1‐adrenoceptor‐mediated contractile activity in caudal arterial smooth muscle from Type 2 diabetic Goto‐Kakizaki rats

1. In the present study, we compared the responsiveness of de‐endothelialized caudal artery smooth muscle strips, isolated from Type 2 diabetic Goto‐Kakizaki (GK) and normal Wistar rats, to α₁‐adrenoceptor stimulation (cirazoline) and membrane depolarization (K⁺). 2. The contractile and myosin 20 kDa light chain (LC₂₀) phosphorylation responses to 0.3 μmol/L cirazoline of caudal artery strips isolated from 12‐week‐old GK rats were significantly reduced compared with those of age‐matched Wistar rats, whereas the contractile and LC₂₀ phosphorylation responses to 60 mmol/L K⁺ were unaltered. 3. Stimulation of fura 2‐AM‐loaded strips from GK rats with 0.3 μmol/L cirazoline induced a significantly smaller rise in [Ca²⁺]_i (by ～20%) compared with that in strips from Wistar rats, whereas comparable Ca²⁺ transients were evoked by K⁺ in both. 4. Using quantitative polymerase chain reaction, no significant differences were detected in the mRNA expression of α_1A‐, α_1B‐ and α_1D‐adrenoceptor subtypes between GK and Wistar rats. 5. Cirazoline (1 μmol/L)‐ and caffeine (20 mmol/L)‐induced contractions in the absence of extracellular Ca²⁺ were unaltered in GK rats, suggesting that the release of Ca²⁺ from the sarcoplasmic reticulum in response to cirazoline does not differ between GK and Wistar rats. 6. The results of the present study suggest that Ca²⁺ entry from the extracellular space via α₁‐adrenoceptor‐activated, Ca²⁺‐permeable channels, but not via membrane depolarization and voltage‐gated L‐type Ca²⁺ channels, is impaired in caudal artery smooth muscle of GK rats.     

Specific Role of α2A‐ and α2B‐, but not α2C‐, Adrenoceptor Subtypes in the Inhibition of the Vasopressor Sympathetic Out‐flow in Diabetic Pithed Rats

Several lines of evidence have shown an association of diabetes with a catecholamines' aberrant homeostasis involving a drastic change in the expression of adrenoceptors. This homeostatic alteration includes, among other things, atypical actions of α₂‐adrenoceptor agonists within central and peripheral α₂‐adrenoceptors (e.g. profound antinociceptive effects in diabetic subjects). Hence, this study investigated the pharmacological profile of the α₂‐adrenoceptor subtypes that inhibit the vasopressor sympathetic out‐flow in streptozotocin‐pre‐treated (diabetic) pithed rats. For this purpose, B‐HT 933 (up to 30 μg/kg min) was used as a selective α₂‐adrenoceptor agonist and rauwolscine as a non‐selective α_2A/2B/2C‐adrenoceptor antagonist; in addition, BRL 44408, imiloxan and JP‐1302 were used as subtype‐selective α_2A‐, α_2B‐ and α_2C‐adrenoceptor antagonists, respectively (all given i.v.). I.v. continuous infusions of B‐HT 933 inhibited the vasopressor responses induced by electrical sympathetic stimulation without affecting those by i.v. bolus injections of noradrenaline in both normoglycaemic and diabetic rats. Interestingly, the ED₅₀ for B‐HT 933 in diabetic rats (25 μg/kg min) was almost 1‐log unit greater than that in normoglycaemic rats (3 μg/kg.min). Moreover, the sympatho‐inhibition induced by 10 μg/kg min B‐HT 933 in diabetic rats was (i) abolished by 300 μg/kg rauwolscine or 100 and 300 μg/kg BRL 44408; (ii) partially blocked by 1000 μg/kg imiloxan; and (iii) unchanged by 1000 μg/kg JP‐1302. Our findings, taken together, suggest that B‐HT 933 has a less potent inhibitory effect on the sympathetic vasopressor responses in diabetic (compared to normoglycaemic) rats and that can probably be ascribed to a down‐regulation of α_2C‐adrenoceptors.     

Isoeugenodilol: A vasorelaxant α/β‐adrenoceptor blocker with antioxidant activity

Isoeugenodilol, derived from isoeugenol, was investigated under in vivo and in vitro conditions. Isoeugenodilol (0.1, 0.5, 1.0, and 3.0 mg kg^–1, i.v.) produced dose‐dependent hypotensive and bradycardia responses in pentobarbital‐anesthetized Wistar rats. Isoeugenodilol (0.5 mg kg^–1, i.v.) also markedly inhibited both the tachycardia effects induced by (‐) isoproterenol and arterial pressor responses induced by phenylephrine. A single oral administration of isoeugenodilol at doses of 10, 30, and 100 mg kg^–1 dose‐dependently reduced blood pressure, with a decrease in heart rate in conscious spontaneously hypertensive rats (SHRs). In the isolated Wistar rat right atria, left atria, and guinea pig tracheal strips, isoeugenodilol competitively antagonized the (‐) isoproterenol‐induced positive chronotropic effects, inotropic effects, and tracheal relaxation effects in a concentration‐dependent manner. The parallel shift to the right of the concentration–response curve of (‐) isoproterenol suggested that isoeugenodilol was a β₁/β₂‐adrenoceptor competitive antagonist. The apparent pA₂ values were 7.33 ± 0.12 in the right atria, 7.80 ± 0.09 in the left atria, and 7.26 ± 0.11 in the trachea, indicating that isoeugenodilol was a nonselective β‐adrenoceptor blocker. In thoracic aorta experiments, isoeugenodilol also produced a competitive antagonism of norepinephrine‐induced contraction with a pA₂ value of 7.47 ± 0.45. In isolated atria of reserpinized rats, cumulative additions of isoeugenodilol and propranolol produced significantly cardiodepressant responses at high concentrations (10^–5 M) and were without intrinsic sympathomimetic activity (ISA). In isolated rat thoracic aorta, isoeugenodilol more potently relaxed the contractions induced by norepinephrine (3 × 10^–6 M) than those by high K⁺ (75 mM). The vasorelaxant effects of isoeugenodilol on norepinephrine‐induced contractions were attenuated by pretreatment with tetraethylammonium (TEA) and glibenclamide, implying the involvement of K⁺ channel opening. In addition, isoeugenodilol inhibited norepinephrine‐induced biphasic contraction; it affected the fast phase significantly more than the slow phase. Furthermore, the binding characteristics of isoeugenodilol and various β‐adrenoceptor antagonists were evaluated in [³H]CGP‐12177 binding to rat ventricle and lung tissues and [³H]prazosin binding to brain membranes. The ranking order of inhibition for [³H]CGP‐12177 binding on β‐adrenoceptor was propranolol > labetalol > isoeugenodilol, and that for [³H]prazosin binding to α‐adrenoceptors was isoeugenodilol > labetalol. Furthermore, isoeugenodilol inhibited lipid peroxidation induced by Fe²⁺ and ascorbic acid with IC₅₀ of 0.74 ± 0.03 mM, indicating that it possesses the antioxidant activity inherent in isoeugenol. In conclusion, isoeugenodilol was found to be a new generation α/β‐adrenoceptor antagonist with vasorelaxant activity by inhibiting Ca²⁺ channel, receptor‐mediated Ca²⁺ mobilization and by K⁺ channel opening, and to have additional potentially antioxidant effects. Drug Dev. Res. 51:29–42, 2000. © 2000 Wiley‐Liss, Inc.     

Pharmacological characterization of the inhibitory effect of (R)-α-methylhistamine on sympathetic cardiopressor responses in the pithed guinea-pig

1 The effect of (R)-α-methylhistamine (R-α-mHA), a selective histamine H₃-receptor agonist, on increases in blood pressure and heart rate mediated by activation of the sympathetic nervous system induced by electrical stimulation of the spinal cord, was characterized in the vagotomized, pithed guinea-pig. 2 The frequency-dependent nature of (R)-α-mHA's effect on sympathetic cardiopressor responses was studied at frequencies between 1 and 20 Hz. (R)-α-mHA (10–100 μg kg^?1, i.v.) produced a dose-dependent inhibition of the stimulated increase in both blood pressure (BP) and heart rate (HR). The inhibition was inversely related to frequency and maximum inhibition (BP, 61% at 1 Hz; HR, 50% at 1 Hz) was seen with 100 μg kg^?1 of (R)-α-mHA. Treatment with the H₃ receptor inactive stereoisomer, (S)-α-methylhistamine (300 αg kg^?1, i.v.) did not inhibit the neurogenic sympathetic cardiopressor responses. 3 Pretreatment with thioperamide (1 mg kg^?1, i.v.), a histamine H₃ receptor antagonist, blocked (R) -α-mHA's inhibitory effect on stimulation-induced sympathetic cardiopressor responses. 4 Combined pretreatment with the H₃-receptor antagonist cimetidine (3 mg kg^?1, i.v.) and the H₁-receptor antagonist chlorpheniramine (0.3 mg kg^?1, i.v.) did not attenuate (R) -α-mHA's inhibitory effects. 5 (R) -α-mHA (100 μg kg^?1) had no effect on the hypertensive or tachycardia effects induced by adrenaline (1 and 3 μg kg^?1, i.v.). 6 Treatment with a combination of prazosin (1 mgkg^?1, i.v.) and yohimbine (1.5 mg kg^?1, i.v.) to block α₁ and α₂-adrenoceptors, abolished the sympathetic hypertension without affecting the inhibition of sympathetic tachycardia induced by (R) -α-mHA. Conversely, pretreatment with the β-adrenoceptor antagonist propranolol (1 mg kg^?1, i.v.), which blocked the sympathetic tachycardia, did not block (R)-α-mHA's inhibition of sympathetic hypertensive responses. 7 In adrenalectomized guinea-pigs, (R) -α-mHA (100μg kg^?1, i.v.) also produced a frequency-dependent inhibition of sympathetic hypertensive cardiopressor responses that was not significantly different from intact animals. 8 These results demonstrate that (R) -α-mHA produces a frequency-dependent inhibition of the cardiopressor responses due to activation of the sympathetic innervation to the resistance vessels and the heart. These effects of (R)-α-mHA are mediated by a prejunctional inhibitory H₃-receptor mechanism, and an intact CNS is not needed to elicit these effects. The most likely site of action is on the postganglionic sympathetic neuroeffector junction whereas a site in the adrenal medulla, unlike the sympathetic ganglia can be excluded. Furthermore, the inhibitory modulation of the sympathetic tachycardia responses with (R)-α-mHA is not affected by α₁- and α₂-adrenoceptor blockade.     

Syntheses,calcium channel modulation effects,and nitric oxide release studies of O2‐alkyl‐1‐(pyrrolidin‐1‐yl) diazen‐1‐ium‐1,2‐diolate 4‐aryl(heteroaryl)‐1,4‐dihydro‐2,6‐dimethyl‐3‐nitropyridine‐5‐carboxylates

A group of racemic 4‐aryl(heteroary)‐1,4‐dihydro‐2,6‐dimethyl‐3‐nitropyridine‐5‐carboxy‐lates possessing a potential nitric oxide donor C‐5 O²‐alkyl‐1‐(pyrrolidin‐1‐yl)diazen‐1‐ium‐1,2‐diolate ester [alkyl=(CH₂)_n, n=1–4] substituent were synthesized using a modified Hantzsch reaction. Compounds having a C‐4 2‐trifluoromethylphenyl ( 16 ), 2‐pyridyl ( 17 ), or benzofurazan‐4‐yl ( 20 ) substituent generally exhibited more potent smooth‐muscle calcium channel antagonist activity (IC₅₀ values in the 0.55 to 38.6 μM range) than related analogs having a C‐4 3‐pyridyl ( 18 ), or 4‐pyridyl ( 19 ) substituent with IC₅₀ values > 29.91 μM, relative to the reference drug nifedipine (IC₅₀=0.0143 μM). The point of attachment of C‐4 isomeric pyridyl substituents was a determinant of antagonist activity where the relative potency profile was 2‐pyridyl > 3‐pyridyl and 4‐pyridyl. Subgroups of compounds 16a–d , 17a–d , and 20a–d having alkyl spacer groups of variable chain length [–CO₂(CH₂)_nO–, n=1–4] exhibited small differences in calcium channel antagonist potency. Replacement of the ester “methyl” moiety of Bay K 8644 by an O²‐alkyl‐1‐(pyrrolidin‐1‐yl)diazen‐1‐ium‐1,2‐diolate group provided the Bay K 8644 group of analogs 16a‐d that retained the desired cardiac positive inotropic effect. The most potent compound in this group, O²‐ethyl‐1‐(pyrrolidin‐1‐yl)diazen‐1‐ium‐1,2‐diolate 1,4‐dihydro‐2,6‐dimethyl‐3‐nitro‐4‐(2‐trifluoromethylphenyl)pyridine‐5‐carboxylate ( 16b , EC₅₀=0.096 μM) is about eightfold more potent positive inotrope (cardiac calcium channel agonist) than the reference compound Bay K 8644 (EC₅₀=0.77 μM). A similar replacement of the ester “isopropyl” group in the C‐4 benzofurazan‐4‐yl group of compounds by an O²‐alkyl‐1‐(pyrrolidin‐1‐yl)diazen‐1‐ium‐1,2‐diolate ester substituent provided compounds 20 (n=1 and 4) that were approximately equipotent cardiac positive inotropes with the parent reference compound PN 202‐791 ( 3 , EC₅₀=9.40 μM). The O²‐alkyl‐1‐(pyrrolidin‐1‐yl)diazen‐1‐ium‐1,2‐diolate ester moiety present in 1,4‐dihydropyridine calcium channel modulating compounds 16–20 is not a suitable ?NO donor moiety because the percent nitric oxide released upon in vitro incubation with either l ‐cysteine, rat serum, or pig liver esterase was less than 1%. Drug Dev. Res. 60:204–216, 2003. © 2003 Wiley‐Liss, Inc.     

Functional and radioligand binding characterization of the α1L‐adrenoceptor subtype of the human vas deferens

相似文献   

α‐Adrenoceptor‐Mediated Modulation of 5‐HT2 Receptor Agonist Induced Impulsive Responding in a 5‐Choice Serial Reaction Time Task

Abstract: The activation of 5‐HT_2A receptors has been shown to enhance the probability of premature responding, regarded as a form of motor impulsive behaviour. At the behavioural level, the interaction of α‐adrenoceptors and 5‐HT₂ receptors has been linked to head twitch behaviour, regarded as an experimental model of compulsive behaviour. The aim was to determine whether the probability of premature responding induced by an excess activation of 5‐HT_2A receptors can be modulated by the blockade of α₁‐ or α₂‐ adrenoceptors. In the experiments, the 5‐choice serial reaction time task was used to measure attention and response control of the rats. The experiments assessed the effects of (±)‐1‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane hydrochloride (DOI) 0.1–0.2 mg/kg subcutaneously, a 5‐HT_2A/2C agonist, and prazosin, an α₁–adrenoceptor antagonist, alone or in combination, on the performance of rats. In an additional experiment to examine the possible role of the α₂–adrenoceptors, a potent, selective and specific α₂–adrenoceptor antagonist, atipamezole, was given alone or in combination with DOI. Results showed that DOI increased the probability of premature responses, but it did not affect the choice accuracy. Prazosin (0.1 or 0.3 mg/kg, subcutaneously), given on its own had no effects on probability of responding prematurely, but prazosin (0.3 mg/kg.) was able to attenuate the DOI‐induced responding. Atipamezole (0.1 mg/kg, s.c.) did not attenuate the effect of DOI on probability of premature responding. When given at lower doses, DOI (0.03 mg/kg) and atipamezole (0.03 mg/kg) synergistically increased the probability of premature responding, whereas a higher dose of atipamezole (0.3 mg/kg) on its own increased the probability of responding prematurely, but this effect was not additive to that of 0.1 mg/kg DOI. These data indicate that 5‐HT₂ receptor activation enhances impulsive responding and this effect can be diminished by the blockade of α₁‐adrenoceptors. Atipamezole, an α₂‐antagonist, enhances the probability of premature responding and shares the mechanism of action with the 5‐HT₂ agonist in this respect. These results provide evidence for an interaction between the serotonergic 5‐HT₂ receptors and α‐adrenoceptors in the modulation of response control to the motor impulsivity type of behaviour (premature responding) in addition to that of compulsory behaviour (head shakes) found previously.